Ultime notizie per Savara (NASDAQ:SVRA) Azioni

SAVARA INC

Savara

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Savara Inc

Ark Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKR#NASDAQ">ARKR</a>) reported quarterly losses of $(2.57) per share. This is a 542.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported $39.73 million in sales this quarter. This is a 5.99 percent decrease over sales of $42.26 million the same period last year.

Earnings

News

ARKR

Ark Restaurants Q2 EPS $(2.57) Down From $(0.40) YoY, Sales $39.73M Down From $42.26M YoY

<ul>
<li>Received overwhelming shareholder approval with 99.9% of votes cast in favor</li>
<li>Simplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments</li>
<li>Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years</li>
<li>Royalty Pharma's diversified royalty portfolio to be combined with intellectual capital and investment platform of the Manager to advance shareholder value creation</li>
</ul>
&nbsp;Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of Shareholders (the "Meeting"), marking a key milestone for the company.
"We are pleased to announce shareholder approval of our manager internalization, an important step that strengthens our corporate governance, enhances transparency, and further aligns our leadership team with shareholder interests," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "We are grateful for the strong support from our shareholders, and remain focused on delivering long-term value through our differentiated, innovation-focused business model."
With shareholder approval, Royalty Pharma will proceed with its transition from an external manager model to an integrated corporate structure, with the Royalty Pharma executive team and employees becoming direct employees of the company.
Key Benefits to Shareholders
The transaction is expected to result in multiple benefits for shareholders. On a financial basis, the acquisition is expected to reduce costs and enhance economic returns on investments. Specifically, the acquisition will generate cash savings of greater than $100 million in 2026 and greater than $175 million in 2030, and drive cumulative savings of greater than $1.6 billion over ten years. The acquisition also increases shareholder alignment, enhances corporate governance, ensures management continuity, maximizes employee retention as a result of the 5 to 9 year vesting of the shares received by management and simplifies Royalty Pharma's corporate structure. Lastly, internalizing the Manager has the potential to expand Royalty Pharma's&nbsp;shareholder base&nbsp;and further enhance the company's valuation over time.

RPRX

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition With 99.9% Votes Cast In Favor

General

ACHR

PLTR

Archer Says Has Forged A Partnership With Palantir To Build Artificial Intelligence For 'The Future Of Next-gen Aviation Technologies'

Montana Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $(0.06) by 533.33 percent. This is a 192.86 percent increase over losses of $(0.28) per share from the same period last year.

Earnings Beats

AIRJ

Montana Technologies Q1 EPS $0.26 Beats $(0.06) Estimate

Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) will report on Q1 2025.

Lument Finance Trust reported Q1 2025 Adj EPS $0.08

NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 47.62 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $13.38 million which beat the analyst consensus estimate of $4.26 million by 213.97 percent. This is a 869.91 percent increase over sales of $1.38 million the same period last year.

Earnings Misses

NuScale Power Q1 EPS $(0.11) Misses $(0.09) Estimate, Sales $13.38M Beat $4.26M Estimate

Dividends

MSIF

MSC Income Fund Announces Regular Quarterly Dividend Of $0.35/Shr And Supplemental Quarterly Dividend Of $0.01/Shr

Barclays analyst Adrienne Yih maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Equal-Weight and lowers the price target from $70 to $60.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Nike, Lowers Price Target to $60

MSC Income Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSIF#NYSE">MSIF</a>) reported quarterly earnings of $0.38 per share. This is a 5.56 percent increase over earnings of $0.36 per share from the same period last year. The company reported $33.23 million in sales this quarter. This is a 2.13 percent decrease over sales of $33.95 million the same period last year.

MSC Income Fund Q1 EPS $0.38 Up From $0.36 YoY, Sales $33.23M Down From $33.95M YoY

Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) reported first-quarter financial results Monday after the bell. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/05/b45359248/archer-announces-first-quarter-results-highlighting-on-track-uae-launch-new-launch-edition-custome">company&#8217;s report</a>.
Q1 Earnings: Archer Aviation, which designs electric vertical take-off and landing (eVTOL) aircraft, reported a first-quarter loss of 17 cents per share, beating analyst <a href="http://benzinga.com/quote/achr/earnings">estimates</a> for a loss of 28 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Archer highlighted the announcement of its first two customers for its Midnight Edition launch in the first quarter and said it plans to deliver its first Midnight aircraft to the UAE in the coming months, with planned deployment slated for later this year.
The company also highlighted a partnership it signed with Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) in the first quarter to build AI for the future of next-generation aviation technologies. The companies plan to work together to develop AI software to improve a range of aviation systems.
Archer said its quarterly spending stayed within the previously guided range. The company ended the period with $1.03 billion in cash and cash equivalents, the highest cash position in company history. 
&#8220;Archer&#8217;s pushing the boundaries of what&#8217;s possible and reshaping the future of aviation for years to come.&nbsp;This quarter, the team made strong progress across our civil and defense efforts as we continue to deepen our strategic partner relationships and prepare for commercialization in the UAE later this year,&#8221; said&nbsp;Adam Goldstein, founder and CEO of Archer.
Archer reported an adjusted EBITDA loss of $109 million in the quarter and guided for a second-quarter adjusted EBITDA loss of $100 million to $120 million.
Archer Aviation executives will further discuss the quarter on a call with investors and analysts at 5 p.m. ET.
ACHR Price Action: <a href="http://benzinga.com/quote/achr" target="_blank" rel="noreferrer noopener">Archer Aviation shares</a> were up 5.29% in Monday&#8217;s after-hours session, trading at $9.56 at the time of publication, per <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black</a></li>
</ul>
Photo: courtesy of Archer Aviation.

Guidance

After-Hours Center

Movers

Archer Aviation Reports Smaller-Than-Expected Loss In Q1, Company Says UAE Launch Remains 'On Track' For 2025, Shares Surge

Management

IFBD

Infobird Says On May 7 Xiangyang Wen Was Appointed As CEO

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) affirms FY2025 Adj EPS guidance from $2.50-$2.80 to $2.50-$2.80 vs $2.65 analyst estimate. Affirms FY2025 sales outlook from $3.30 billion-$3.40 billion to $3.30 billion-$3.40 billion vs $3.34 billion estimate.

ACHC

Acadia Healthcare Co Affirms FY2025 Adj EPS Guidance of $2.50-$2.80 vs $2.65 Est; Affirms FY2025 Sales Guidance of $3.30B-$3.40B vs $3.34B Est

Barclays analyst Adrienne Yih maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Equal-Weight and lowers the price target from $309 to $276.

LULU

Barclays Maintains Equal-Weight on Lululemon Athletica, Lowers Price Target to $276

Star Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STHO#NASDAQ">STHO</a>) reported quarterly losses of $(0.57) per share. This is a 84.51 percent increase over losses of $(3.68) per share from the same period last year. The company reported $14.62 million in sales this quarter. This is a 42.51 percent decrease over sales of $25.44 million the same period last year.

STHO

Star Hldgs Q1 EPS $(0.57) Up From $(3.68) YoY, Sales $14.62M Down From $25.44M YoY

- Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral presentation today by Andrea Palermo, M.D., from the Campus Bio-Medico University (Rome), during ESPE &amp; ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE).
The PaTH Forward Trial included a 4-week randomized, double-blind, placebo-controlled period followed by an open-label extension period through Week 266. Renal function was assessed by estimated glomerular filtration rate (eGFR). Bone turnover markers C-terminal telopeptide of type 1 collagen (CTx) and procollagen type 1 N-terminal propeptide (P1NP), as well as bone mineral density (BMD) measured by DXA scan, were assessed at baseline and regular intervals through Week 214. Safety assessments included 24-hour urine-calcium and treatment-emergent adverse events (TEAEs). At Week 214, 56 of the original 59 patients enrolled (95%) remained in the open-label extension portion of the trial.
At Week 214, nearly all patients (98%) continued to have normal albumin-adjusted serum calcium levels and 93% remained independent from conventional therapy (defined as taking &lt; 600mg/day of calcium and not taking active vitamin D). Bone turnover markers CTx and P1NP increased from the low end of normal at baseline, peaked by Week 26, then declined and remained stable above baseline levels through Week 214. The data also showed continued improvement in skeletal dynamics, with BMD remaining within age- and sex-matched norms. In addition, at Week 214, most participants (67.8%) had a clinically meaningful (≥ 5&nbsp;mL/min/1.73 m2) increase in eGFR from baseline, with changes in eGFR evident at Week 4.
In the trial, TransCon PTH treatment was generally well-tolerated, with no new safety signals identified. TEAEs were mostly mild or moderate and no serious TEAEs or discontinuations were related to study drug.
"We set out to address the underlying cause of disease and are pleased to see this long-term data reinforcing the safety profile and durability of response in patients treated with TransCon PTH, including sustained normalization of skeletal dynamics and significant and sustained improvements in kidney function," said&nbsp;Aimee Shu,&nbsp;M.D.&nbsp;Executive Vice President of Endocrine &amp; Rare Disease Medical Science and Chief Medical Officer at Ascendis Pharma.

Biotech

ASND

Ascendis Pharma Announces New Data From Week 214 Of Its Phase 2 Path Forward Trial Showing That Long-Term Treatment With TransCon PTH Continued To Provide A Durable Response In Adults With Hypoparathyroidism

Buybacks

Axos Financial Reveals $100M Increase To The Existing Stock Repurchase Program

Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 32 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $421.00 thousand which missed the analyst consensus estimate of $1.27 million by 66.79 percent. This is a 75.48 percent decrease over sales of $1.72 million the same period last year.

Cue Biopharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $421.00K Miss $1.27M Estimate

Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.33) by 6.02 percent. This is a 36.89 percent decrease over losses of $(1.03) per share from the same period last year.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Jasper Therapeutics Q1 EPS $(1.41) Misses $(1.33) Estimate

RBOT

Vicarious Surgical Collaborates With UMass Memorial Medical Center To Support Adoption And Utilization Of Its Robotic System Through Perioperative Practices

GoPro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRO#NASDAQ">GPRO</a>) is looking for Q2 Adj EPS of $(0.11)-$(0.03) vs $(0.12) analyst estimate. sees sales of $135.000 million-$155.000 million vs $124.65 million analyst estimate.

GPRO

GoPro Sees Q2 Adj EPS $(0.11)-$(0.03) vs $(0.12) Est; Sees Sales $135.000M-$155.000M vs $124.65M Est

Penny Stocks

Small Cap

Press Releases

Savara Announces Participation in the Leerink Global Healthcare Conference

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Comments

Savara

Notizie

Ultime notizie per Savara (NASDAQ:SVRA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO